Low-dose Gemtuzumab-Ozogamicin as post-consolidation therapy in elderly patients with acute myeloid leukaemia: A pilot study: Correspondence

British Journal of Haematology

Volumn 150, Issue 1, 2010, Pages 119-120

  Poloni, Antonella ^a   Capelli, Debora ^a   Trappolini, Silvia ^a   Costantini, Benedetta ^a   Montanari, Mauro ^a   Gini, Guido ^a   Scortechini, Ilaria ^a   Mancini, Giorgia ^a   Discepoli, Giancarlo ^b   Leoni, Pietro ^a   Olivieri, Attilio ^c  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b OSPEDALI RIUNITI   (Italy)

^c SAN CARLO HOSPITAL   (Italy)

Author keywords

AML; Chemotherapy; Elderly; Immunotherapy; Transplantation

Indexed keywords

CD33 ANTIGEN; GEMTUZUMAB OZOGAMICIN; GLYCOPROTEIN P; GRANULOCYTE COLONY STIMULATING FACTOR; MULTIDRUG RESISTANCE PROTEIN 1;

ACUTE GRANULOCYTIC LEUKEMIA; ANAPHYLAXIS; ANTIGEN BINDING; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHROMOSOME ABERRATION; CLINICAL TRIAL; CYTOGENETICS; DISEASE FREE SURVIVAL; DRUG EFFICACY; HUMAN; HYPERTRANSAMINASEMIA; INCIDENCE; KARYOTYPE; LETTER; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTOSIS; LOW DRUG DOSE; MAINTENANCE THERAPY; MONOTHERAPY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; RISK FACTOR;

EID: 77953482002     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08168.x     Document Type: Letter

References (8)

1. Appelbaum, F.R., Gundacker, H., Head, D.R., Slovak, M.L., Willman, C.L., Godwin, J.E., Anderson, J.E. Petersdorf, S.H. (2006) Age and acute myeloid leukaemia. Blood, 107, 3481 3485.
2. Bross, P.F., Beitz, J., Chen, G., Chen, X.H., Duffy, E., Kieffer, L., Roy, S., Sridhara, R., Rahman, A., Williams, G. Pazdur, R. (2001) Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clinical Cancer Research, 7, 1490 1496.
3. Cascavilla, N., D'Arena, G., Greco, M.M., Melillo, L., Merla, E. Carella, A.M. (2008) Gemtuzumab-Ozogamicin as maintenance therapy after Autologous Stem Cell Transplantation in elderly patients with Acute Myeloid Leukaemia. British Journal of Haematology, 142, 852 853.
4. Keating, S., Suciu, S., de Witte, T., Zittoun, R., Mandelli, F., Belhabri, A., Amadori, S., Fibbe, W., Gallo, E., Fillet, G., Varet, B., Meloni, G., Hagemeijer, A., Fazi, P., Solbu, G., Willemze, R., EORTC Leukemia Group GIMEMA Leukemia Group. (2003) The stem cell mobilizing capacity of patients with acute myeloid leukemia in complete remission correlates with relapse risk: results of EORTC-GIMEMA AML 10 trial. Leukemia, 17, 60 67.
5. Larson, R.A., Boogaerts, M., Estey, E., Karanes, C., Stadtmauer, E.A., Sievers, E.L., Mineur, P., Bennett, J.M., Berger, M.S., Eten, C.B., Munteanu, M., Loken, M.R., Van Dongen, J.J., Bernstein, I.D., Appelbaum, F.R. Mylotarg Study Group. (2002) Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia, 16, 1627 1636.
6. Olivieri, A., Capelli, D., Troiani, D., Poloni, A., Montanari, M., Offidani, M., Discepoli, G. Leoni, P. (2007) A new intensive induction schedule, including high-dose Idarubicin, high-dose Aracytin and Amifostine, in older AML patients: feasibility and long-term results in 42 patients. Experimental Hematology, 35, 1074 1082.
7. Sievers, E.L., Larson, R.A., Stadtmauer, E.A., Estey, E., Löwenberg, B., Dombret, H., Karanes, C., Theobald, M., Bennett, J.M., Sherman, M.L., Berger, M.S., Eten, C.B., Loken, M.R., Van Dongen, J.J., Bernstein, I.D., Appelbaum, F.R. Mylotarg Study Group. (2001) Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. Journal of Clinical Oncology, 19, 3244 3254.
8. Taksin, A.L., Legand, O., Raffoux, E., de Revel, T., Thomas, X., Contenin, N., Bouabdallah, R., Pautas, C., Turlure, P., Reman, O., Gardin, C., Varet, B., de Botton, S., Pousset, F., Farhat, H., Chevret, S., Dombret, H. Castaigne, S. (2007) High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group. Leukemia, 21, 66 71.